Medical condition
Ovarian Cancer
Ovarian Cancer is a medical condition tracked by NovaPharmaNews across 8 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- paclitaxel (PACLITAXEL ACCORD) Antineoplastic and immunomodulating agents (L01)
- doxorubicin hydrochloride (CELDOXOME PEGYLATED LIPOSOMAL) Antineoplastic and immunomodulating agents (L01)
- melphalan (ALKERAN) Antineoplastic and immunomodulating agents (L01)
- olaparib (LYNPARZA) Antineoplastic and immunomodulating agents (L01)
- trabectedin (YONDELIS) Antineoplastic and immunomodulating agents (L01)
- pembrolizumab (KEYTRUDA) Antineoplastic and immunomodulating agents (L01)
- doxorubicin (ADRIAMYCIN) Antineoplastic and immunomodulating agents (L01)
- cediranib maleate (ZEMFIRZA) Antineoplastic and immunomodulating agents (L01)
Latest Ovarian Cancer news
OSE Immunotherapeutics' Tedopi Ovarian Cancer Trial Results Selected for ASCO 2026 Presentation
OSE Immunotherapeutics announces TEDOVA Phase 2 trial results for Tedopi in ovarian cancer will be presented at ASCO 2026, marking key milestone for immunotherapy.
Labcorp Launches FDA-Approved PD-L1 Companion Diagnostic for KEYTRUDA Ovarian Cancer Treatment
Labcorp launches nationwide availability of FDA-approved PD-L1 IHC 22C3 pharmDx companion diagnostic to identify ovarian cancer patients eligible for KEYTRUDA treatment.
Debiopharm's Lunresertib Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer Treatment
Debiopharm announces FDA Fast Track designation for Lunresertib combination therapy targeting genomic-defined platinum-resistant ovarian cancer patients.
FDA Approves Elahere: Expanded Use for Platinum-Resistant Ovarian Cancer
The FDA has approved Elahere for expanded use in patients with platinum-resistant ovarian cancer, marking a significant advancement in treatment options.
FDA Approval Mirvetuximab Soravtansine: Accelerated OK for Elahere in Ovarian Cancer
The FDA has granted accelerated approval for Mirvetuximab Soravtansine, branded as Elahere, offering new hope for patients with ovarian cancer.